Hanmi Pharm Co Ltd
KRX:128940
Intrinsic Value
Hanmi Pharmaceutical Co., Ltd. engages in the manufacture and sale of pharmaceutical products. [ Read More ]
The intrinsic value of one
Hanmi Pharm Co Ltd
stock under the Base Case scenario is
370 006.29
KRW.
Compared to the current market price of 324 500 KRW,
Hanmi Pharm Co Ltd
is
Undervalued by 12%.
Hanmi Pharm Co Ltd's market capitalization is 4T KRW.
Hanmi Pharm Co Ltd stock price is 324 500 KRW.
Hanmi Pharm Co Ltd stock price (324500 KRW) is 12% less than its Intrinsic Value (370 006.29 KRW).
Hanmi Pharm Co Ltd stock (303 264.23 KRW) is 7% less than its price (324500 KRW). Open DCF Valuation
Hanmi Pharm Co Ltd stock price (324500 KRW) is 26% less than its Relative Value (436 748.36 KRW). Open Relative Valuation
Hanmi Pharm Co Ltd has upside potential of 30% compared to the average analyst price target.
Open Wall St Estimates
Hanmi Pharm Co Ltd has positive Operating Income for the last twelve months.
Hanmi Pharm Co Ltd's short-term assets (731B KRW) exceed its short-term liabilties (705B KRW).
Hanmi Pharm Co Ltd's ROIC (Return on Invested Capital) for the past 12 months is positive and is equal to 12%.
Hanmi Pharm Co Ltd has positive Net Debt. This means that the company has more debt (425B KRW) than cash and short-term investments (254B KRW).
Hanmi Pharm Co Ltd has positive three-year average ROE (Return on Equity): 9%. The company is efficient at transforming stockholders' equity into net income.
Hanmi Pharm Co Ltd's Revenue has grown by 12% over the past 12 months.
Hanmi Pharm Co Ltd's ROE (Return on Equity) for the past 12 months is positive and is equal to 16%.
Hanmi Pharm Co Ltd has positive Net Income for the last twelve months.
Hanmi Pharm Co Ltd has positive three-year average ROIC (Return on Invested Capital): 7%. The company is efficient at using invested capital to generate operating income.
Hanmi Pharm Co Ltd's Revenue is forecast to grow at a rate of 11% per year over the next 3 years.
Hanmi Pharm Co Ltd's ROIC (Return on Invested Capital) has increased in the last 3 years from 2% to 12%.
Hanmi Pharm Co Ltd's Revenue has been growing by 11% per year for the last 3 years.
Hanmi Pharm Co Ltd's ROE (Return on Equity) has significantly increased in the last 3 years from 3% to 16%.
Hanmi Pharm Co Ltd has positive Free Cash Flow for the last twelve months.
Hanmi Pharm Co Ltd's long-term assets (2T KRW) exceed its long-term liabilties (943B KRW).
Hanmi Pharm Co Ltd generates enough operating income (221B KRW) to cover interest payments on its debt (28B KRW).
Hanmi Pharm Co Ltd has positive Gross Profit for the last twelve months.
Hanmi Pharm Co Ltd's D/E (Debt to Equity) is very low and is equal to 0.45.
Hanmi Pharm Co Ltd's Altman Z-Score is very high and is equal to 4.46.
Valuation Backtest
Hanmi Pharm Co Ltd
Run backtest to discover the historical profit from buying and selling
Hanmi Pharm Co Ltd
stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Hanmi Pharm Co Ltd
Balance Sheet Decomposition
Hanmi Pharm Co Ltd
| Current Assets | 730.6B |
| Cash & Short-Term Investments | 254.2B |
| Receivables | 179B |
| Other Current Assets | 297.5B |
| Non-Current Assets | 1.2T |
| Long-Term Investments | 45B |
| PP&E | 860.2B |
| Intangibles | 81B |
| Other Non-Current Assets | 181.7B |
| Current Liabilities | 704.8B |
| Accounts Payable | 45.2B |
| Accrued Liabilities | 56.8B |
| Short-Term Debt | 336.1B |
| Other Current Liabilities | 266.7B |
| Non-Current Liabilities | 238.5B |
| Long-Term Debt | 89.1B |
| Other Non-Current Liabilities | 149.4B |
Earnings Waterfall
Hanmi Pharm Co Ltd
|
Revenue
|
1.5T
KRW
|
|
Cost of Revenue
|
-661.6B
KRW
|
|
Gross Profit
|
829.2B
KRW
|
|
Operating Expenses
|
-608.6B
KRW
|
|
Operating Income
|
220.7B
KRW
|
|
Other Expenses
|
-74.5B
KRW
|
|
Net Income
|
146.2B
KRW
|
Free Cash Flow Analysis
Hanmi Pharm Co Ltd
Profitability Score
Profitability Due Diligence
Hanmi Pharm Co Ltd's profitability score is 58/100. The higher the profitability score, the more profitable the company is.
Score
Hanmi Pharm Co Ltd's profitability score is 58/100. The higher the profitability score, the more profitable the company is.
Solvency Score
Solvency Due Diligence
Hanmi Pharm Co Ltd's solvency score is 61/100. The higher the solvency score, the more solvent the company is.
Score
Hanmi Pharm Co Ltd's solvency score is 61/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
Price Targets Summary
Hanmi Pharm Co Ltd
According to Wall Street analysts, the average 1-year price target for
Hanmi Pharm Co Ltd
is 423 033.74 KRW
with a low forecast of 337 656.81 KRW and a high forecast of 532 350 KRW.
Shareholder Return
Price
Hanmi Pharm Co Ltd
| Average Annual Return | -4.89% |
| Standard Deviation of Annual Returns | 22.27% |
| Max Drawdown | -47% |
| Market Capitalization | 4T KRW |
| Shares Outstanding | 12 690 528 |
| Percentage of Shares Shorted |
N/A
|
Company Profile
Hanmi Pharm Co Ltd
Country
Industry
Market Cap
Dividend Yield
Description
Hanmi Pharmaceutical Co., Ltd. engages in the manufacture and sale of pharmaceutical products. The company is headquartered in Hwaseong, Gyeonggi-Do. The company went IPO on 2010-07-30. The firm operates its business through three segments. The Pharmaceuticals segment manufactures and sells tablets, capsules, injections, syrups, powders and raw materials used in the treatment of hypertension, reflux esophagitis, influenza type A and influenza type B virus infections and hyperlipidemia, among others. The Other segment is engaged in the materials processing. The Export segment produces and sells products such as powders and injections, and exports technologies.
Contact
IPO
Employees
Officers
The intrinsic value of one
Hanmi Pharm Co Ltd
stock under the Base Case scenario is
370 006.29
KRW.
Compared to the current market price of 324 500 KRW,
Hanmi Pharm Co Ltd
is
Undervalued by 12%.
You don't have any saved screeners yet
